Olaparib (CAS 763113-22-0)

Application and positioning

Olaparib is an oral poly(ADP-ribose) polymerase (PARP) inhibitor that traps PARP on DNA and exploits synthetic lethality in BRCA-mutated cells. It is used in tablets and capsules for BRCA-mutated ovarian, breast, pancreatic and prostate cancers, and as maintenance therapy in relapsed ovarian cancer. Laurand supplies it from audited Chinese production partners for pharmaceutical manufacturing and process development.

Quality and documentation

• Batch-specific Certificate of Analysis issued by the manufacturing site
• SDS/MSDS and specification sheet available on request
• Residual solvents and elemental impurities statements discussed per project
• For pharmaceutical manufacturing and R&D use only — not for direct administration

Packaging and handling

• Packed in double polyethylene-lined fibre drums; pack size confirmed at quotation
• Small quantities in sealed aluminium foil bags
• Palletised for air and sea freight; store dry, ventilated and protected from light

Related products

• Pazopanib Hydrochloride (CAS 635702-64-6)
• Ponatinib Hydrochloride (CAS 1114544-31-8)
• Poziotinib (CAS 1092364-38-9)
• Regorafenib Hydrate (CAS 1019206-88-2)
• 9-Bromo-6,11-dihydro-8-hydroxy-6,6-dimethyl-11-oxo-5H-benzo[b]carbazole-3-carbonitrile (CAS 1256579-06-2)

Specifications shown are indicative. The final specification and documentation package are confirmed with the quotation.